Related Experiment Video
Updated: Jul 26, 2026

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
Published on: November 20, 2011
Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing
Paula Guerrero-López1, Pilar Alamán-Díez1, Soraya Hernández-Hatibi1
1Multiscale in Mechanical and Biological Engineering, Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
Abstract:
Drug delivery research strongly depends on experimental models that faithfully mimic the tumor microenvironment (TME) and its barriers to evaluate therapeutic efficacy. Conventional systems provide valuable insights but suffer from some limitations in physiological relevance, reproducibility, scalability or translational predictability. In this context, microfluidic 'tumor-on-chip' platforms have emerged as innovative tools that integrate engineering technology to model biological complexity, offering controlled microenvironments to investigate drug penetration, transport dynamics, and therapeutic response. A distinctive aspect of these microsystems is the possibility of incorporating matrices that mimic the extracellular matrix (ECM) of different tissues. These matrices enhance the ability of the in vitro models to replicate the structural, biochemical, and mechanical features of solid tumors. In this review, we focus on the application of microfluidic matrix-integrated tumor-on-chip platforms for drug delivery evaluation. We first outline key microenvironmental features that regulate therapeutic efficacy and discuss how they can be engineered within microfluidic models. We then examine how transport dynamics and delivery mechanisms are modeled under physiologically relevant conditions and review the use of these platforms to assess a broad range of therapeutic strategies, including nanocarriers, biologics, and gene- and cell-based therapies. Finally, we highlight emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools. These models aim to bridge the gap between simplified in vitro assays and more complex in vivo studies, ultimately accelerating the translation of drug delivery systems into clinical practice and paving the way for more personalized therapeutic strategies.
More Related Videos
Related Concept Videos
In Vitro Drug Dissolution: Compendial Testing Models I
In Vitro Drug Dissolution: Compendial Testing Models II

